Trastuzumab/Pertuzumab/Chemo Does Not Confer Response Advantage in Gastric/GEJ Cancer
Trastuzumab/pertuzumab/chemotherapy was associated with higher rates of toxicity and no mpRR improvement vs chemotherapy alone in HER2+ gastric cancer.
Related Articles
Subcutaneous Isatuximab Plus Pd Meets Coprimary End Points, Proves Noninferior to IV Administration in R/R Multiple Myeloma
Subcutaneous isatuximab plus Pd led to a noninferior ORR and observed concentration before dosing at steady state vs IV isatuximab plus Pd in RRMM.
ASH 2024 press briefing rundown: treating not-so-benign hematology conditions
VJHemOnc is thrilled to bring you the latest updates from the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, held in New Orleans,…
QuANTUM-First exploratory analysis: Quizartinib maintenance in patients with newly diagnosed FLT3-ITD AML
We summarize key results of an exploratory analysis from the phase III QuANTUM-First trial evaluating the efficacy of quizartinib vs placebo maintenance therapy in patients…
World Cancer Day 2025: International Journal of Cancer
The International Journal of Cancer is a cancer journal from the Union for International Cancer Control covering experimental and clinical cancer research.
Blinatumomab Becomes Standard Addition to Consolidation Chemo in B-ALL, Irrespective of MRD Status
Daniel DeAngelo, MD, PhD, discusses the expanded role of blinatumomab in B-cell precursor acute lymphoblastic leukemia management
The future of ovarian cancer: innovation, treatment and hope
The future of ovarian cancer: innovation, treatment and hope
Duvelisib Plus Venetoclax Is Active in Relapsed/Refractory CLL and Richter Syndrome
Duvelisib plus venetoclax was active in relapsed/refractory CLL and Richter syndrome with high-risk, TP53-aberrant disease after BTK inhibition.
Durvalumab Plus Vaccine Therapy Elicits ‘Encouraging’ DFS in BCG-Unresponsive NMIBC
Durvalumab plus vaccine therapy demonstrated evidence of preliminary antitumor activity without substantial additive toxicity in BCG-unresponsive NMIBC.
Retifanlimab Emerges as Potential New SOC in Advanced SCAC
Sheela Rao, MBBS, MD, FRCP, discusses data from the phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab plus chemotherapy vs chemotherapy in advanced SCAC.
17th Annual Hematologic Malignancies Demystified 2025 | Virtual
Register now for HMD 2025 and explore groundbreaking advancements in hematology. Stay informed with the latest innovations shaping the future of hematology research presented at…
